GlassScriptPhysician profile
Harmanpreet B Rakhra
NPI 1417919481
$9,875.22
in general payments reported to CMS, 2019-2025
48 companies · $2,021 in 2025
The $2,021 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $390 · 2021: $1,457 · 2022: $1,118 · 2023: $1,653 · 2024: $1,589 · 2025: $2,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,244 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,243.56 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,563.78 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $973.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $903.90 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $886.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $781.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.38 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $577.66 | 2019-2025 | |
| Abbvie INC. | $521.52 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $354.44 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $308.30 | 2019-2024 | Verquvo, Gardasil 9, Gardasil |
| Amgen INC. | $265.27 | 2019-2025 | Otezla, Repatha, Repatha |
| Neurocrine Biosciences, INC. | $256.69 | 2023-2025 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $214.43 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $202.20 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $130.13 | 2023-2025 | Uptravi, Opsumit |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmanpreet Rakhra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.